Galapagos: What deal should we be looking for now?

BUY, Fair Value EUR52 vs. EUR50 (+42%)
News published on October Thursday 1, 2015
Share on

Having notified Galapagos that it is backing out of the deal on filgotinib to focus on its own JAK inhibitor, in our view AbbVie has opened the way for several pharmaceutical companies to take a closer look at filgotinib’s significant potential. With a phase III trial to start in H1 2016 and more than eight partners sitting around the negotiating table, it is now more relevant than ever to consider how Big Pharma might be valuing filgotinib.


For more information, please contact marketing@bryangarnier.com  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities